Latest Breaking News On - Research commercialisation fund - Page 6 : comparemela.com

Share this article Share this article Research on preventative COVID-19 nasal spray published in prestigious, peer-reviewed academic journals: EBioMedicine and the European Respiratory Journal Novel therapy developed by Australian biotech company, Ena Respiratory, shown in animal study to reduce COVID-19 virus levels in the nose and throat by up to 96%; also found to be effective against rhinovirus (common cold), the predominant cause of the common cold and exacerbations of chronic respiratory diseases including asthma and COPD Mode of action complementary to COVID-19 vaccines, once weekly nasal spray to play significant role in reducing COVID-19 community transmission and disease progression in at risk populations

New south walesChristophe demaisonCaleb hulme moirDavid jacksonNathan bartlettCiara byrneViral immunologist at hunter medical research instituteResearch commercialisation fundMana communicationsDepartment of microbiologyBiomedical translation fundUniversity of melbournePublic health englandProfessor miles carroll at public health englandPeter doherty institute for infectionEuropean respiratory journal